Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Stereotactic Ablative Radiotherapy’s Value Studied

Cancer; ePub 2017 Dec 20; Siva, Louie, et al

Stereotactic ablative radiotherapy (SABR) appears to be well tolerated and can effectively treat renal cell carcinoma, according to a study involving 223 individuals. Moreover, those who receive single-fraction SABR seem to have a lower risk of distant progression and death. Participants averaged 72 years of age, were from 9 international registries, and received either single- (n=118) or multi- (n=105) fraction SABR. Investigators looked at survival according to patient, tumor, and treatment characteristics. Among the results:

  • 36% of patients experienced grade 1/2 toxicities; 1% had grade 3/4 toxicities.
  • 98% experienced local control at 2 years; cancer-specific and progression-free survival rates were 96% and 77%, respectively.
  • These rates at 4 years were 98%, 92%, and 65%, respectively.
  • Patients with larger tumors were 16% more likely to experience poor progression-free survival; they were 28% more likely to have poor cancer-specific survival.
  • Those receiving multifraction SABR were also more likely to experience these outcomes (13% and 33%, respectively).

Citation:

Siva S, Louie A, Warner A, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). [Published online ahead of print December 20, 2017]. Cancer. doi:10.1002/cncr.31156.

This Week's Must Reads

Overall survival factor in metastatic ccRCC, Thiery-Vuillemin A et al. Clinical Genitourinary Cancer 2018; 16: e297-e305

High perirenal fat thickness predicts poor progression-free survival in patients with localized ccRCC, Huang H et al. Urologic Oncology: Seminars and Original Investigations 2018; 36: 157.e1-157.e6

AXL linked to worse outcome of metastatic RCCs treated with sunitinib, Zucca L E et al. Urologic Oncology: Seminars and Original Investigations 2018: 36; 11.e13-11.e21

Pathologic predictors in lymph node dissection of metastatic RCC, Chipollini J et al. Clinical Genitourinary Cancer 2018; 16: Pages e443-450.

Plated-lymphocyte ratio is correlated with poor prognosis in RCC, Wang Z et al. Clinica Chimica Acta; 2018; 480: 166-72.

Must Reads in Renal Cell Carcinoma

Overall survival factor in metastatic ccRCC, Thiery-Vuillemin A et al. Clinical Genitourinary Cancer 2018; 16: e297-e305

High perirenal fat thickness predicts poor progression-free survival in patients with localized ccRCC, Huang H et al. Urologic Oncology: Seminars and Original Investigations 2018; 36: 157.e1-157.e6

AXL linked to worse outcome of metastatic RCCs treated with sunitinib, Zucca L E et al. Urologic Oncology: Seminars and Original Investigations 2018: 36; 11.e13-11.e21

Pathologic predictors in lymph node dissection of metastatic RCC, Chipollini J et al. Clinical Genitourinary Cancer 2018; 16: Pages e443-450.

Plated-lymphocyte ratio is correlated with poor prognosis in RCC, Wang Z et al. Clinica Chimica Acta; 2018; 480: 166-72.